The U.S. Food and Drug Administration is weighing whether to halt a safety study involving thousands of patients taking GlaxoSmithKline PLC's Avandia diabetes drug, a decision that could also determine whether the drug stays on the U.S. market.
via online.wsj.com
No comments:
Post a Comment